Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States, according to manufacturer Boehringer Ingelheim.
Striverdi Respimat is a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The product is not indicated to treat asthma or acute deteriorations of COPD, the company noted.
The product was approved by the FDA in July 2014 and is a long-acting beta agonist (LABA) delivered via the Respimat inhaler, which provides a pre-measured amount of medicine in a slow-moving mist that helps patients inhale the medicine. The Respimat inhaler was developed to actively deliver medication in a way that does not depend on how fast air is breathed in from the inhaler.
“For over a half century, Boehringer Ingelheim has been a leader in discovering and developing new therapies for respiratory diseases. We’re proud to build upon our respiratory heritage by bringing Striverdi Respimat to market as a new COPD maintenance treatment option,” said Kathleen M. Dowd, senior vice president, Marketing, Boehringer Ingelheim Pharmaceuticals, Inc.
See the drug’s full prescribing information here. [pdf]